SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): **October 22, 2010**

BioTime, Inc.

(Exact name of registrant as specified in its charter)

California	**1-12830**	**94-3127919**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1301 Harbor Bay Parkway, Suite 100
Alameda, California 94502
(Address of principal executive offices)

(510) 521-3390
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Statements made in this Report that are not historical facts may constitute forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed. Such risks and uncertainties include but are not limited to those discussed in this report and in BioTime's other reports filed with the Securities and Exchange Commission. Words such as "expects," "may," "will," "anticipates," "intends," "plans," "believes," "seeks," "estimates," and similar expressions identify forward-looking statements.

Section 8 – Other Events

Item 8.01 – Other Events

On November 1, 2010 our subsidiary Embryome Sciences, Inc. will add 12 new human embryonic progenitor cell lines to its product line for research use. The 12 new cell lines are designated B28, EN23, Z3, EN5, RASMO19, EN27, T42, SK47, SM2, SK46, T44, and SK44, and were produced from embryonic stem cells using Embryome Sciences' ACTCellerate™ technology.

In addition to offering these new progenitor cell lines, we will also simultaneously launch corresponding cell culture media and differentiation kits. Information about the products will be available online at www.embryome.com/products.htm beginning November 1, 2010.

New data has been obtained on three of Embryome Sciences' previously announced progenitor cell lines. Cell line SK17 has the potential to differentiate into cells that express renin and smooth muscle cell-related genes characteristic of the juxtaglomerular apparatus of the kidney. Cell line Z2, when differentiated using a proprietary protocol, expresses relatively high levels of the bone growth factor genes BMP2 and BMP7 (also known as osteogenic protein-1 (OP-1). Cell line J16 expresses preadipocyte markers of interest to researchers in cosmetic dermatology and type II diabetes.

Human embryonic progenitor cells are intermediate in the developmental process between embryonic stem cells and fully differentiated cells. The cells may possess the ability to become a wide array of cell types with potential applications in research, drug discovery, and potential novel regenerative stem cell therapies. The cells are relatively easy to manufacture on a large scale and in a purified state, which may make it advantageous to work with these cells compared to the direct use of human embryonic stem cells.

On October 22, 2010, we announced for the first time our PureStem™ technology with which we plan to expand our product offerings in calendar year 2011. Our PureStem™ technology utilizes the expression of exogenous transcriptional regulators that control the differentiation of human embryonic stem cells and induced plutipotent stem cells, and may potentially provide many of the human cell types needed in regenerative medicine. We are seeking patent protection for the PureStem™ technology.

Section 9-Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

Exhibit Number	Description
99.1	Press release dated October 22, 2010

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOTIME, INC.

Date: October 22, 2010

By: /s/ Robert W. Peabody
Senior Vice President, Chief Operating
Officer and Chief Financial Officer

Exhibit Number	Description
99.1	Press release dated October 22, 2010

Exhibit 99.1

BioTime's CEO Michael West Presents 12 New ACTCellerate™ Cell Lines and New PureStem™ Products Slated for Launch in 2011 at GTCbio Stem Cell Conference Today

ALAMEDA, Calif.--(BUSINESS WIRE)--October 22, 2010--BioTime, Inc. (NYSE Amex:BTIM) announced that the Company's CEO Dr. Michael West will present data today relating to 12 new cell lines, differentiation kits, and cell culture media at the GTCbio 4th Advances in Stem Cell Discovery and Development Conference in San Francisco, California. Dr. West's presentation titled: "Fate Space Screening of Clonal Human ES-derived Embryonic Progenitor Cell Lines" will include a discussion of the Company's proprietary bank of more than 140 diverse human cell types made from human embryonic stem cells, the company's screening technology for discovering means of manufacturing human cell types, and the potential use of these cells for diverse new therapeutics and drug discovery.

During his lecture, Dr. West will describe the 12 new lines: B28, EN23, Z3, EN5, RASMO19, EN27, T42, SK47, SM2, SK46, T44, and SK44 that will be launched beginning November 1, 2010. He also will disclose new data on the cell lines: SK17 that have the potential to differentiate into cells that express renin and smooth muscle cell-related genes characteristic of the juxtaglomerular apparatus of the kidney, Z2 that when differentiated using a proprietary protocol expresses relatively high levels of the bone growth factor genes BMP2 and BMP7 (also known as osteogenic protein-1 (OP-1), and J16 that expresses preadipocyte markers of interest to researchers in cosmetic dermatology and type II diabetes.

In addition, Dr. West will disclose for the first time the Company's PureStem™ technology, with which the Company plans to expand its product offerings in calendar year 2011. The PureStem™ technology utilizes the expression of exogenous transcriptional regulators to control the differentiation of human embryonic stem cells and induced plutipotent stem cells, and may potentially provide many new human cell types needed in regenerative medicine. BioTime is seeking patent protection for the PureStem™ technology.

Additional information about these new products will be found at www.embryome.com beginning on November 1, 2010. Dr. West's presentation is available on BioTime's website at www.biotimeinc.com.

The annual GTCbio Stem Cell Research & Therapeutics Conference provides information regarding cutting-edge developments in all areas of stem cell research including the biology, medicine, applications, regulations, and business of stem cells. This year's conference will address recent developments in pre-clinical and clinical trials of stem cell therapy, regenerative medicine and tissue engineering, cancer stem cells, stem cell reprogramming, FDA and NIH policies regarding funding for stem cell research, and private funding from the pharmaceutical industry.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is developed through subsidiaries focused on specific fields of applications. BioTime develops and markets research products in the field of stem cells and regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. BioTime's therapeutic product development strategy is pursued through subsidiaries that focus on specific organ systems and related diseases for which there is a high unmet medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences, Ltd. is developing therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases. Cell Cure's minority shareholder Teva Pharmaceutical Industries has optioned its OpRegen^{TM} retinal cell product for use in the treatment of Age-related Macular Degeneration (AMD). BioTime's subsidiary OrthoCyte Corporation is developing therapeutic applications of stem cells to treat orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation, focuses on the therapeutic applications of stem cell technology in cancer. BioTime's Singapore subsidiary, ES Cell International Pte Ltd, has been at the forefront of advances in human embryonic stem ("hES") cell technology, having been one of the earliest distributors of hES cell lines to the research community. ESI has produced clinical-grade human embryonic stem cell lines that were derived following principles of good manufacturing practice and currently offers them for potential use in therapeutic product development. In addition to its stem cell products, BioTime develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, and technology for use in surgery, emergency trauma treatment and other applications. BioTime's lead product, Hextend®, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements. Additional information about BioTime, Embryome Sciences, Cell Cure, OrthoCyte, OncoCyte, BioTime Asia, and ESI can be found on the web at www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company’s business, particularly those mentioned in the cautionary statements found in the company’s Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list:
http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0

CONTACT:
BioTime, Inc.
Judith Segall, 510-521-3390 ext. 301
jsegall@biotimemail.com